Latest News

Cure SMA Updates Health Insurance Road Map to Support Patients and Families

October 17, 2025
Posted in , ,

Cure SMA has updated its Health Insurance Road Map to help patients, families, and providers navigate the complexities of health insurance. The updated resource reflects the current healthcare landscape and […]

Read More ›

Cure SMA and the Luke 18:1 Foundation Launch New Fold & Go Wheelchair Grant Program

October 8, 2025
Posted in , ,

Cure SMA is excited to announce the launch of a brand-new equipment grant program, made possible through the generous support of the Luke 18:1 Foundation. This program will provide Fold […]

Read More ›

Cure SMA Update on SMA Treatment Delays

September 24, 2025
Posted in , ,

Dear SMA Community, Yesterday was a disappointing and frustrating day for our community. We learned of two FDA approval delays for Scholar Rock’s apitegromab and Biogen’s high-dose nusinersen/Spinraza. While there […]

Read More ›

Biogen Receives News on Supplemental New Drug Application (sNDA) for High Dose Nusinersen from the U.S. FDA

September 23, 2025
Posted in , ,

Today, Biogen announced that the U.S. Food and Drug Administration (FDA) has delayed the approval with a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for the high-dose […]

Read More ›

Scholar Rock Receives News on Biologics License Application (BLA) for Apitegromab from the U.S. FDA

September 23, 2025
Posted in , ,

Today, Scholar Rock announced that the U.S. Food and Drug Administration (FDA) has delayed the approval with a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) for […]

Read More ›

Cure SMA 2025 Hill Day: 24 Hours of Advocacy Impact

September 18, 2025
Posted in , , ,

On Tuesday, September 16, about 150 adults with spinal muscular atrophy (SMA) and family members of children with SMA visited Capitol Hill to advocate for key priorities of the SMA […]

Read More ›
Scroll to Top